Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB X NZW)F1 lupus mice

Elaine V. Lourenço, Claudio Procaccini, Francesca Ferrera, Noriko Iikuni, Ram P. Singh, Gilberto Filaci, Giuseppe Matarese, Fu Dong Shi, Ernest Brahn, Bevra H. Hahn, Antonio La Cava

Research output: Contribution to journalArticle

Abstract

Treatment of (NZB X NZW)F1 (NZB/W) lupus-prone mice with the anti-DNA Ig-based peptide pConsensus prolongs the survival of treated animals and effectively delays the appearance of autoantibodies and glomerulonephritis. We have previously shown that part of these protective effects associated with the induction of CD4+CD25+Foxp3+ regulatory T cells (Tregs) that suppressed autoantibody responses. Because the effects of pConsensus appeared secondary to qualitative rather than quantitative changes in Tregs, we investigated the molecular events induced by tolerance in Tregs and found that signaling pathways including ZAP70, p27, STAT1, STAT3, STAT6, SAPK, ERK, and JNK were not significantly affected. However, peptide tolerization affected in Tregs the activity of the MAPK p38, whose phosphorylation was reduced by tolerance. The pharmacologic inhibition of p38 with the pyridinyl imidazole inhibitor SB203580 in naive NZB/W mice reproduced in vivo the effects of peptide-induced tolerance and protected mice from lupus-like disease. Transfer experiments confirmed the role of p38 in Tregs on disease activity in the NZB/W mice. These data indicate that the modulation of p38 activity in lupus Tregs can significantly influence the disease activity.

Original languageEnglish
Pages (from-to)7415-7421
Number of pages7
JournalJournal of Immunology
Volume182
Issue number12
DOIs
Publication statusPublished - Jun 15 2009

Fingerprint

p38 Mitogen-Activated Protein Kinases
Regulatory T-Lymphocytes
Inbred NZB Mouse
Autoantibodies
Peptides
DNA
Glomerulonephritis
Phosphorylation

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB X NZW)F1 lupus mice. / Lourenço, Elaine V.; Procaccini, Claudio; Ferrera, Francesca; Iikuni, Noriko; Singh, Ram P.; Filaci, Gilberto; Matarese, Giuseppe; Shi, Fu Dong; Brahn, Ernest; Hahn, Bevra H.; Cava, Antonio La.

In: Journal of Immunology, Vol. 182, No. 12, 15.06.2009, p. 7415-7421.

Research output: Contribution to journalArticle

Lourenço, EV, Procaccini, C, Ferrera, F, Iikuni, N, Singh, RP, Filaci, G, Matarese, G, Shi, FD, Brahn, E, Hahn, BH & Cava, AL 2009, 'Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB X NZW)F1 lupus mice', Journal of Immunology, vol. 182, no. 12, pp. 7415-7421. https://doi.org/10.4049/jimmunol.0804214
Lourenço, Elaine V. ; Procaccini, Claudio ; Ferrera, Francesca ; Iikuni, Noriko ; Singh, Ram P. ; Filaci, Gilberto ; Matarese, Giuseppe ; Shi, Fu Dong ; Brahn, Ernest ; Hahn, Bevra H. ; Cava, Antonio La. / Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB X NZW)F1 lupus mice. In: Journal of Immunology. 2009 ; Vol. 182, No. 12. pp. 7415-7421.
@article{a283ad9001d84d4687de69a8e73a6056,
title = "Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB X NZW)F1 lupus mice",
abstract = "Treatment of (NZB X NZW)F1 (NZB/W) lupus-prone mice with the anti-DNA Ig-based peptide pConsensus prolongs the survival of treated animals and effectively delays the appearance of autoantibodies and glomerulonephritis. We have previously shown that part of these protective effects associated with the induction of CD4+CD25+Foxp3+ regulatory T cells (Tregs) that suppressed autoantibody responses. Because the effects of pConsensus appeared secondary to qualitative rather than quantitative changes in Tregs, we investigated the molecular events induced by tolerance in Tregs and found that signaling pathways including ZAP70, p27, STAT1, STAT3, STAT6, SAPK, ERK, and JNK were not significantly affected. However, peptide tolerization affected in Tregs the activity of the MAPK p38, whose phosphorylation was reduced by tolerance. The pharmacologic inhibition of p38 with the pyridinyl imidazole inhibitor SB203580 in naive NZB/W mice reproduced in vivo the effects of peptide-induced tolerance and protected mice from lupus-like disease. Transfer experiments confirmed the role of p38 in Tregs on disease activity in the NZB/W mice. These data indicate that the modulation of p38 activity in lupus Tregs can significantly influence the disease activity.",
author = "Louren{\cc}o, {Elaine V.} and Claudio Procaccini and Francesca Ferrera and Noriko Iikuni and Singh, {Ram P.} and Gilberto Filaci and Giuseppe Matarese and Shi, {Fu Dong} and Ernest Brahn and Hahn, {Bevra H.} and Cava, {Antonio La}",
year = "2009",
month = "6",
day = "15",
doi = "10.4049/jimmunol.0804214",
language = "English",
volume = "182",
pages = "7415--7421",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB X NZW)F1 lupus mice

AU - Lourenço, Elaine V.

AU - Procaccini, Claudio

AU - Ferrera, Francesca

AU - Iikuni, Noriko

AU - Singh, Ram P.

AU - Filaci, Gilberto

AU - Matarese, Giuseppe

AU - Shi, Fu Dong

AU - Brahn, Ernest

AU - Hahn, Bevra H.

AU - Cava, Antonio La

PY - 2009/6/15

Y1 - 2009/6/15

N2 - Treatment of (NZB X NZW)F1 (NZB/W) lupus-prone mice with the anti-DNA Ig-based peptide pConsensus prolongs the survival of treated animals and effectively delays the appearance of autoantibodies and glomerulonephritis. We have previously shown that part of these protective effects associated with the induction of CD4+CD25+Foxp3+ regulatory T cells (Tregs) that suppressed autoantibody responses. Because the effects of pConsensus appeared secondary to qualitative rather than quantitative changes in Tregs, we investigated the molecular events induced by tolerance in Tregs and found that signaling pathways including ZAP70, p27, STAT1, STAT3, STAT6, SAPK, ERK, and JNK were not significantly affected. However, peptide tolerization affected in Tregs the activity of the MAPK p38, whose phosphorylation was reduced by tolerance. The pharmacologic inhibition of p38 with the pyridinyl imidazole inhibitor SB203580 in naive NZB/W mice reproduced in vivo the effects of peptide-induced tolerance and protected mice from lupus-like disease. Transfer experiments confirmed the role of p38 in Tregs on disease activity in the NZB/W mice. These data indicate that the modulation of p38 activity in lupus Tregs can significantly influence the disease activity.

AB - Treatment of (NZB X NZW)F1 (NZB/W) lupus-prone mice with the anti-DNA Ig-based peptide pConsensus prolongs the survival of treated animals and effectively delays the appearance of autoantibodies and glomerulonephritis. We have previously shown that part of these protective effects associated with the induction of CD4+CD25+Foxp3+ regulatory T cells (Tregs) that suppressed autoantibody responses. Because the effects of pConsensus appeared secondary to qualitative rather than quantitative changes in Tregs, we investigated the molecular events induced by tolerance in Tregs and found that signaling pathways including ZAP70, p27, STAT1, STAT3, STAT6, SAPK, ERK, and JNK were not significantly affected. However, peptide tolerization affected in Tregs the activity of the MAPK p38, whose phosphorylation was reduced by tolerance. The pharmacologic inhibition of p38 with the pyridinyl imidazole inhibitor SB203580 in naive NZB/W mice reproduced in vivo the effects of peptide-induced tolerance and protected mice from lupus-like disease. Transfer experiments confirmed the role of p38 in Tregs on disease activity in the NZB/W mice. These data indicate that the modulation of p38 activity in lupus Tregs can significantly influence the disease activity.

UR - http://www.scopus.com/inward/record.url?scp=67649213042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649213042&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0804214

DO - 10.4049/jimmunol.0804214

M3 - Article

C2 - 19494264

AN - SCOPUS:67649213042

VL - 182

SP - 7415

EP - 7421

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -